The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
CAR-T Meeting 2025 | The incidence of atrial arrhythmias following CAR-T and the risk factors for this complication
Roni Shouval, MD, PhD, Memorial Sloan Kettering Cancer Center, New York, NY, notes that atrial arrhythmias are a common cardiac adverse event following CAR T-cell therapy, occurring in between 5-12% of patients, with a significant proportion of these events being atrial fibrillation. Dr Shouval highlights two key risk factors for the occurrence of these arrhythmias: pre-existing arrhythmia before CAR-T treatment and the type of CAR T-cell product used. This interview took place at the EHA-EBMT 7th European CAR T-cell Meeting, held in Strasbourg, France.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
So when considering among the potential cardiac adverse events, it seems like atrial arrhythmias are probably the most common complications. We see it somewhere between 5 to 12 percent depending on the study.
We performed an analysis of about 230 patients with non-Hodgkin lymphoma treated with CD19-directed CAR T-cells and there we found an incidence of about 10% of atrial arrhythmias...
So when considering among the potential cardiac adverse events, it seems like atrial arrhythmias are probably the most common complications. We see it somewhere between 5 to 12 percent depending on the study.
We performed an analysis of about 230 patients with non-Hodgkin lymphoma treated with CD19-directed CAR T-cells and there we found an incidence of about 10% of atrial arrhythmias. These were primarily atrial fibrillation.
When looking at the risk factors for these arrhythmias, the main one was pre-existing arrhythmia before CAR-T, so the patients came in normal sinus rhythm to the treatment but then develop a recurrence during the treatment itself. And the second risk factor was the type of CAR T-cell product. So CAR T-cell products with CD28 costimulatory domain were much more likely to invoke essentially or to be associated with atrial arrhythmias compared to the 4-1BB products.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
Disclosures
Speaker Honorarium from Incyte.
